Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.

Wu YY, Yen MF, Yu CP, Chen HH.

Br J Cancer. 2013 Jun 11;108(11):2241-9. doi: 10.1038/bjc.2013.202. Epub 2013 May 14.


Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates.

Wu YY, Yen MF, Yu CP, Chen HH.

Risk Anal. 2014 Feb;34(2):367-79. doi: 10.1111/risa.12116. Epub 2013 Sep 23.


Added cancer yield of breast magnetic resonance imaging screening in women with a prior history of chest radiation therapy.

Freitas V, Scaranelo A, Menezes R, Kulkarni S, Hodgson D, Crystal P.

Cancer. 2013 Feb 1;119(3):495-503. doi: 10.1002/cncr.27771. Epub 2012 Sep 5.


Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement.

Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K.

Breast Cancer Res. 2012 Feb 7;14(1):R25.


Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.

Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen HH.

Breast Cancer Res Treat. 2010 Jul;122(2):553-66. doi: 10.1007/s10549-009-0701-x. Epub 2010 Jan 7.


Breast cancer detection risk in screening mammography after a false-positive result.

Castells X, Román M, Romero A, Blanch J, Zubizarreta R, Ascunce N, Salas D, Burón A, Sala M; Cumulative False Positive Risk Group.

Cancer Epidemiol. 2013 Feb;37(1):85-90. doi: 10.1016/j.canep.2012.10.004. Epub 2012 Nov 9.


MRI in the early detection of breast cancer in women with high genetic risk.

Trecate G, Vergnaghi D, Manoukian S, Bergonzi S, Scaperrotta G, Marchesini M, Ferranti C, Peissel B, Spatti G, Bohm S, Conti A, Costa C, Sporeni M, Podo F, Musumeci R.

Tumori. 2006 Nov-Dec;92(6):517-23.


Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.

de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ.

J Natl Cancer Inst. 1995 Aug 16;87(16):1217-23.


Should we individualize breast cancer screening?

Desreux J, Bleret V, Lifrange E.

Maturitas. 2012 Nov;73(3):202-5. doi: 10.1016/j.maturitas.2012.08.004. Epub 2012 Sep 14. Review.


Risk of breast cancer after false-positive test results in screening mammography.

von Euler-Chelpin M, Risør LM, Thorsted BL, Vejborg I.

J Natl Cancer Inst. 2012 May 2;104(9):682-9. doi: 10.1093/jnci/djs176. Epub 2012 Apr 5.


Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.


Tumour-related factors and prognosis in breast cancer detected by screening.

Olsson A, Borgquist S, Butt S, Zackrisson S, Landberg G, Manjer J.

Br J Surg. 2012 Jan;99(1):78-87. doi: 10.1002/bjs.7757. Epub 2011 Nov 8.


Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information.

Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA.

J Natl Cancer Inst. 2010 Nov 3;102(21):1618-27. doi: 10.1093/jnci/djq388. Epub 2010 Oct 18.


Effect of false-positive results on reattendance at breast cancer screening programmes in Spain.

Alamo-Junquera D, Murta-Nascimento C, Macià F, Baré M, Galcerán J, Ascunce N, Zubizarreta R, Salas D, Román R, Castells X, Sala M; Cumulative False-Positive Risk Group.

Eur J Public Health. 2012 Jun;22(3):404-8. doi: 10.1093/eurpub/ckr057. Epub 2011 May 9.


Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.

Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM.

BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440.


Prospective breast cancer risk prediction model for women undergoing screening mammography.

Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K.

J Natl Cancer Inst. 2006 Sep 6;98(17):1204-14.


Breast screening outcomes in women with and without a family history of breast and/or ovarian cancer.

Halapy EE, Chiarelli AM, Klar N, Knight J.

J Med Screen. 2004;11(1):32-8.


Impact of intermediate mammography assessment on the likelihood of false-positive results in breast cancer screening programmes.

Ascunce N, Ederra M, Delfrade J, Baroja A, Erdozain N, Zubizarreta R, Salas D, Castells X; Cumulative False Positive Risk (CFPR) Group.

Eur Radiol. 2012 Feb;22(2):331-40. doi: 10.1007/s00330-011-2263-7. Epub 2011 Sep 8.


Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.

Schousboe JT, Kerlikowske K, Loh A, Cummings SR.

Ann Intern Med. 2011 Jul 5;155(1):10-20. doi: 10.7326/0003-4819-155-1-201107050-00003.

Items per page

Supplemental Content

Support Center